Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neurologic Manifestations × Amifampridine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lambert-Eaton Myasthenic Syndrome 3 Rare Diseases 1 Neurologic Manifestations 1 Myasthenia Gravis 1 Mental Disorders 1

Interventions

Bevacizumab 3 Radiosurgery 2 Irinotecan 2 pembrolizumab 1 Vorinostat 1 Valproic Acid 1 Thalidomide 1 Temozolomide 1 Surveys and Questionnaires 1 Sorafenib 1 Sildenafil Citrate 1 Pliability 1 Nivolumab 1 Morphine 1 Methadone 1 Exercise 1 Eating 1 Carboplatin 1 Amifampridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00004832 2015-03-25

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

FDA Office of Orphan Products Development

Phase NA Completed

Mental Disorders, Neurologic Manifestations, Lambert-Eaton Myasthenic Syndrome, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡